Omeros Corp - Company Profile
Powered by 
All the sales intelligence you need on Omeros Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Omeros Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Omeros Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Omeros Corp (Omeros) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company focuses on areas such as complement-mediated diseases, including endothelial injury syndromes, hematopoietic stem cell transplant-associated thrombotic microangiopathy, IgA nephropathy, lupus nephritis, and paroxysmal nocturnal hemoglobinuria. It also focuses on central nervous system disorders, including cocaine use disorder and immuno-oncology. Some of its product candidates include Narsoplimab, OMS1029, and Zaltenibart. The company’s anti-infective therapeutic platform, known as Targeted Complement Activation Therapy (T-CAT), focuses on the treatment of all types of pathogens, including bacteria, fungi, viruses, and parasites. Omeros is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
201 Elliott Avenue West, Seattle, Washington, 98119
Website
www.omeros.com
Telephone
1 206 6765000
No of Employees
175
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OMER (NASD)
EPS
XYZ
Net Income (2024)
XYZ
97.9%
(2024 vs 2023)
Market Cap*
$712.2M
Net Profit Margin (0 vs)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Omeros Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | T-CAT |
| Narsoplimab: Hematopoietic Stem-Cell Transplant-associated Thrombotic Microangiopathy, Covid-19, Acute Respiratory Distress Syndrome | |
| OMS1029: Long-Acting Second-Generation Antibody Targeting Lectin Pathway Disorders | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received US FDA approval for YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). |
| 2025 | Asset Disposal | In December, the company sold global rights to zaltenibart (formerly OMS906), a candidate drug in development for rare blood and kidney disorders, to Novo Nordisk. |
| 2024 | Regulatory Approval | In October, the company received a rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for zaltenibart (OMS906). |
Competitor Comparison
| Key Parameters | Omeros Corp | BioCryst Pharmaceuticals Inc | Supernus Pharmaceuticals Inc | Catalyst Pharmaceuticals Inc | Harrow Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Seattle | Durham | Rockville | Coral Gables | Nashville |
| State/Province | Washington | North Carolina | Maryland | Florida | Tennessee |
| No. of Employees | 175 | 435 | 778 | 182 | 373 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gregory A. Demopulos, M.D. | President; Chairman; Chief Executive Officer | Executive Board | 1994 | 67 |
| David J. Borges | Chief Accounting Officer; Vice President - Finance; Treasurer | Senior Management | 2020 | 62 |
| Andreas Grauer, M.D. | Chief Medical Officer; Vice President | Senior Management | 2023 | 65 |
| George A. Gaitanaris, M.D., Ph.D. | Chief Scientific Officer; Vice President - Science | Senior Management | 2012 | 69 |
| David W. Ghesquiere | Chief Business Development Officer; Vice President | Senior Management | 2024 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer